Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06488911




Registration number
NCT06488911
Ethics application status
Date submitted
28/06/2024
Date registered
5/07/2024
Date last updated
4/10/2024

Titles & IDs
Public title
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
Scientific title
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects With Primary Biliary Cholangitis
Secondary ID [1] 0 0
977-311
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary Biliary Cholangitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - FDC tablet (OCA 5 mg + BZF 400 mg SR)

Experimental: OCA 5 mg + BZF 400 mg SR - Participants will be administered with OCA 5 mg + BZF 400 mg SR once daily.


Treatment: Drugs: FDC tablet (OCA 5 mg + BZF 400 mg SR)
Participants will be administered with FDC tablets once daily.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants reporting adverse events (AE) and serious adverse event (SAE)
Timepoint [1] 0 0
Up to 60 months
Secondary outcome [1] 0 0
Number of participants with 50 percent (%) reduction of pruritus determined by visual analogue scale (VAS) score
Timepoint [1] 0 0
Up to 60 months
Secondary outcome [2] 0 0
Number of participants reporting all-cause mortality
Timepoint [2] 0 0
Up to 60 months
Secondary outcome [3] 0 0
Number of participants with Adjudicated Liver Related Clinical Outcomes - Liver transplant
Timepoint [3] 0 0
Up to 60 months
Secondary outcome [4] 0 0
Number of participants with Adjudicated Liver Related Clinical Outcomes - Progression to hepatic decompensation
Timepoint [4] 0 0
Up to 60 months
Secondary outcome [5] 0 0
Number of participants with Adjudicated Liver Related Clinical Outcomes - Model for End-Stage Liver Disease (MELD) Score =15
Timepoint [5] 0 0
Up to 60 months

Eligibility
Key inclusion criteria
* All subjects with PBC who participated and are actively taking investigational product in Study 747-213 or Study 747-214 are eligible to enroll in this study (977-311).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History or presence of other concomitant liver diseases
* Clinical complications of PBC
* History or presence of hepatic decompensating events
* Current or history of gallbladder disease
* If female, known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2030
Actual
Sample size
Target
133
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Flinders Medical Centre - Bedford Park
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
Argentina
State/province [12] 0 0
Buenos Aires
Country [13] 0 0
Argentina
State/province [13] 0 0
Santa Fe
Country [14] 0 0
Belgium
State/province [14] 0 0
Leuven
Country [15] 0 0
Canada
State/province [15] 0 0
Alberta
Country [16] 0 0
Canada
State/province [16] 0 0
British Columbia
Country [17] 0 0
Croatia
State/province [17] 0 0
Zagreb
Country [18] 0 0
Czechia
State/province [18] 0 0
Hradec Králové
Country [19] 0 0
Czechia
State/province [19] 0 0
Ostrava
Country [20] 0 0
Czechia
State/province [20] 0 0
Plzen
Country [21] 0 0
Estonia
State/province [21] 0 0
Tartu
Country [22] 0 0
France
State/province [22] 0 0
Créteil
Country [23] 0 0
France
State/province [23] 0 0
Lille
Country [24] 0 0
France
State/province [24] 0 0
Paris
Country [25] 0 0
Germany
State/province [25] 0 0
Hanover
Country [26] 0 0
Greece
State/province [26] 0 0
Larissa
Country [27] 0 0
Hungary
State/province [27] 0 0
Debrecen
Country [28] 0 0
Israel
State/province [28] 0 0
Jerusalem
Country [29] 0 0
Italy
State/province [29] 0 0
Bologna
Country [30] 0 0
Korea, Republic of
State/province [30] 0 0
Daegu
Country [31] 0 0
Korea, Republic of
State/province [31] 0 0
Seongnam-si
Country [32] 0 0
Lithuania
State/province [32] 0 0
Vilnius
Country [33] 0 0
Netherlands
State/province [33] 0 0
Amsterdam
Country [34] 0 0
Norway
State/province [34] 0 0
Lørenskog
Country [35] 0 0
Spain
State/province [35] 0 0
Barcelona
Country [36] 0 0
Spain
State/province [36] 0 0
Valencia
Country [37] 0 0
Turkey
State/province [37] 0 0
Ankara
Country [38] 0 0
Turkey
State/province [38] 0 0
Bornova
Country [39] 0 0
Turkey
State/province [39] 0 0
Istanbul
Country [40] 0 0
Turkey
State/province [40] 0 0
Sanliurfa
Country [41] 0 0
United Kingdom
State/province [41] 0 0
Hull
Country [42] 0 0
United Kingdom
State/province [42] 0 0
Newcastle Upon Tyne
Country [43] 0 0
United Kingdom
State/province [43] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Intercept Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of the Fixed-Dose Combination (FDC) of Obeticholic Acid (OCA) and Bezafibrate (BZF) tablet in Subjects with Primary Biliary Cholangitis (PBC).
Trial website
https://clinicaltrials.gov/study/NCT06488911
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Antonio Civitarese, PhD
Address 0 0
Intercept Pharmaceuticals Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06488911